Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GAPDH | P04406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17040469 | 0.86 | CYP3A4 (0.37) | KDM4EGLAGAAMIF | |
| SCHEMBL17037992 | 0.83 | KDM4E (0.37) | KDM4EMEN1MAPTKMT2AGAPDH | |
| SCHEMBL17040468 | 0.78 | KDM4E (0.31) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL17037989 | 0.77 | — | — | |
| SCHEMBL17037919 | 0.77 | CHAT (0.35) | MEN1KMT2A | |
| SCHEMBL17040481 | 0.74 | MIF (0.41) | KDM4EMEN1MAPTMIFKMT2A | |
| SCHEMBL17040372 | 0.74 | — | — | |
| SCHEMBL17040377 | 0.73 | GPR35 (0.31) | — | |
| SCHEMBL17040365 | 0.72 | — | — | |
| SCHEMBL17026642 | 0.70 | CA9 (0.41) | KDM4EMEN1GLAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9547009-B2 | Benzocyclooctyne compounds and uses thereof | ACADEMIA SINICA (TW) | 2017-01-17 | — | — | US | disclosed |
| US-20150241439-A1 | BENZOCYCLOOCTYNE COMPOUNDS AND USES THEREOF | ACADEMIA SINICA (TW) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150241439-A1 | BENZOCYCLOOCTYNE COMPOUNDS AND USES THEREOF | AADAC, TBCA, SPG11 | KDM4E 4661/4885MEN1 3600/4885S1PR4 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.